Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.

摘要: Oxaliplatin (trans-L-diaminocyclohexane oxalatoplatinum, L-OHP) is a novel cisplatin derivative that can improve the side effects of such as toxicity to kidneys and peripheral nerve system. However, L-OHP effective only when combined with 5-Fluorouracil (5-FU) Leucovorin. The relatively low anti-tumor index alone because levels accumulate in tumor tissues due high partitioning erythrocytes vivo. A successful outcome cancer therapy using requires selective delivery concentration drug tumors. present study examines tumor-selective liposomes modified transferrin-conjugated polyethyleneglycol (TF-PEG-liposomes). Delivery these significantly reduced improved circulation time vivo, resulting enhanced extravasation into TF-PEG-liposomes maintained tumors for over 72 h after intravenous injection, which was longer than PEG (PEG-liposomes). Intravenously administered encapsulated within (L-OHP: 5 mg/kg) suppressed growth more effectively PEG-liposomes, Bare-liposomes free L-OHP. Although usually 5-FU Leucovorin, our results suggest has potential therapy.